Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
暂无分享,去创建一个
Y. Shentu | R. Herbst | M. Ahn | E. Felip | M. Dolled-Filhart | P. Baas | Dong-Wan Kim | Joo‐Hang Kim | Ji-Youn Han | J. Pérez-Gracia | J. Molina | M. Garrido | E. Garon | G. Lubiniecki | G. Castro | M. Majem | C. D. Arvis | M. Fidler | E. Im | Shentu Yue
[1] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[2] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[4] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] M. Socinski,et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. , 2015 .
[6] L. Sequist,et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. , 2015 .
[7] Keunchil Park,et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). , 2015 .
[8] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[9] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[10] Yong He. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[12] Andreas Sashegyi,et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.
[13] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[14] R. Herbst,et al. B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction , 2014, Cancer journal.
[15] N. Rizvi,et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. , 2014 .
[16] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[17] Vamsidhar Velcheti,et al. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.
[18] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[19] F. Marincola,et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment , 2013, Journal of Translational Medicine.
[20] V. Sondak,et al. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.
[21] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[22] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[23] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[24] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[25] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[26] Johan Vansteenkiste,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma , 2009 .
[27] M. Lederman,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.
[28] G. Freeman,et al. The B7 family revisited. , 2005, Annual review of immunology.
[29] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[31] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[32] S. Dzik. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .
[33] M Nurminen,et al. Comparative analysis of two rates. , 1985, Statistics in medicine.
[34] B. Efron. The Efficiency of Cox's Likelihood Function for Censored Data , 1977 .